Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy.
A novel "structural difference-based selective etching" strategy has been developed to fabricate hollow/rattle-type mesoporous nanostructures, which was achieved by making use of the structural differences, rather than traditional compositional differences, between the core and the shell of a silica core/mesoporous silica shell structure to create hollow interiors. Highly dispersed hollow mesoporous silica spheres with controllable particle/pore sizes could be synthesized by this method, which show high loading capacity (1222 mg/g) for anticancer drug (doxorubicin). Hemolyticity and cytotoxicity assays of hollow mesoporous silica spheres were conducted, and the synthesized hollow mesoporous silica spheres with large pores show ultrafast immobilization of protein-based biomolecules (hemoglobin). On the basis of this strategy, different kinds of heterogeneous rattle-type nanostructures with inorganic nanocrystals, such as Au, Fe(2)O(3), and Fe(3)O(4) nanoparticles, as the core and mesoporous silica as the shell were also prepared. This strategy could be extended as a general approach to synthesize various hollow/rattle-type nanostructures by creating adequate structural differences between cores and shells in core/shell structures in nanoscale.
Chen
Yu
Y
State Key Laboratory of High Performance Ceramic and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Science, Shanghai 200050, China.
Chen
Hangrong
H
Guo
Limin
L
He
Qianjun
Q
Chen
Feng
F
Zhou
Jian
J
Feng
Jingwei
J
Shi
Jianlin
J
D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000737:chemistry / Q000378:metabolism; D004337:Drug Carriers / Q000138:chemical synthesis / Q000737:chemistry / Q000633:toxicity; D005290:Ferric Compounds / Q000737:chemistry; D052203:Ferrosoferric Oxide / Q000737:chemistry; D006046:Gold / Q000737:chemistry; D006454:Hemoglobins / Q000737:chemistry; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D055767:Immobilized Proteins / Q000737:chemistry; D054118:Nanospheres / Q000737:chemistry; D049329:Nanostructures / Q000737:chemistry* / Q000633:toxicity; D016062:Porosity; D012822:Silicon Dioxide / Q000737:chemistry
D000970:Antineoplastic Agents; D004337:Drug Carriers; D005290:Ferric Compounds; D006454:Hemoglobins; D055767:Immobilized Proteins; C000499:ferric oxide; D006046:Gold; D012822:Silicon Dioxide; D004317:Doxorubicin; D052203:Ferrosoferric Oxide